Pliant Therapeutics, Inc.

As of May 6, 2024, Pliant Therapeutics, Inc. is considered overvalued at $1.25, with unfavorable valuation metrics and a year-to-date return of -90.51%, indicating a significant deterioration in its financial standing compared to peers.

As of June 2, 2025, the trend is mildly bearish due to daily moving averages and weekly Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from the weekly MACD and KST, while the stock is underperforming compared to the S&P 500.

As of March 2022, the management team of Pliant Therapeutics, Inc. includes Dr. Bernard Coulie (CEO), Dr. Hoyoung Huh (Lead Independent Director), Mr. David Pyott, Dr. Suzanne Bruhn, Ms. Gayle Crowell, and Dr. John Curnutte, all serving as directors. They guide the company's strategic direction and operations.

Pliant Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for fibrosis. As of March 2025, it has a market cap of $80.42 million and reported a net profit loss of $56 million.

As of Jun 18, Pliant Therapeutics, Inc. has a market capitalization of 80.42 million, with net sales of 0.00 million and a net profit of -219.51 million for the latest four quarters ending in March 2025. As of December 2024, the company reported shareholder's funds of 304.08 million and total assets of 396.95 million.